Good find, pivalde. Thanks for posting it.

PBT2 and other such drugs in Prana's pipeline may find multiple applications in the future, if the metals thesis turns out to be right. The best scenario is one in which Prana's drugs are approved for Alzheimer's, Parkinson's, surgery (to prevent anesthesia-induced cognitive dysfunction), and as a brain statin for healthy people. Of course, this is pie in the sky at the moment, and the big pharma companies don't seem excited about the potential of Prana's pipeline. Only time will tell. But at the current price I think that Prana is a good long-term speculative play as a small percentage of a diversified stock portfolio.